

A Retrospective Cohort Study for Estimating Incidence Rates of Infusion Site Events for ABBV-951 for the Treatment of Advanced Parkinson's Disease

First published: 15/03/2024

Last updated: 19/06/2025

Study

Planned

Administrative details

EU PAS number

EUPAS1000000050

Study ID

1000000050

DARWIN EU® study

No

Study countries

☐ Finland

☐ France

Study description

The overall aim of this study is to evaluate the effectiveness of additional risk minimization measures (aRMM) by estimating incidence rates of infusion site events (i.e., infusion site infections and/or serious infusion site reactions) in Parkinson disease (PD) patients exposed to ABBV-951 in real-world clinical practice, using data sources from Finland and France. The frequency of infusion site events observed in this real-world study will be interpreted in context of the predefined reference value which is the frequency of the infusion site events reported in the AbbVie clinical trial. The following objectives will be investigated among patients with advanced PD following initiation of treatment with ABBV-951:

- To quantify the incidence rate of first infusion site events (first infusion site infection OR first serious infusion site reactions)
 - To quantify the incidence rate of first infusion site infection
 - To quantify the incidence rate of first serious infusion site reaction
-

Study status

Planned

Research institutions and networks

Institutions

Global Database Studies, IQVIA

- ☐ Czechia
- ☐ Finland
- ☐ Germany

☐ Slovakia

☐ Spain

First published: 17/01/2011

Last updated: 31/07/2024

Institution

Other

ENCePP partner

AbbVie

Contact details

Study institution contact

Mickael Arnaud PAS_registrations@iqvia.com

Study contact

PAS_registrations@iqvia.com

Primary lead investigator

Mickael Arnaud

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/11/2022

Actual: 03/11/2022

Study start date

Planned: 01/09/2026

Data analysis start date

Planned: 01/03/2028

Date of final study report

Planned: 31/12/2029

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

AbbVie Inc.

Study protocol

[P24151-Protocol v1.0_Redacted.pdf](#)(1.24 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Data collection methods:

Secondary use of data

Study design:

A longitudinal, retrospective cohort study of individuals with advanced PD treated with ABBV-951 in Finland and France. The overall study period will be from the date of market availability (anticipated Q4 2023) until Q1 2027. Index date will be defined as the date of first initiation of ABBV-951.

Main study objective:

- To quantify the incidence rate of first infusion site event (first infusion site infection OR first serious infusion site reaction)
- To quantify the incidence rate of first infusion site infection
- To quantify the incidence rate of first serious infusion site reaction

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Name of medicine, other

Foslevodopa/Foscarbidopa

Medical condition to be studied

Parkinson's disease

Population studied

Special population of interest

Immunocompromised

Other

Special population of interest, other

Diabetes Mellitus

Study design details

Outcomes

- Infusion site event (first occurrence only) defined as infusion site infection OR serious infusion site reaction
- Infusion site infection (first occurrence only)
- Serious infusion site reactions (first occurrence only)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Système National des Données de Santé (French national health system main database)

Longitudinal Patient Data - France

Terveydenhuollon hoitoilmoitusrekisteri (Finland Care Register for Health Care)

Data source(s), other

PMSI == Programme de Médicalisation des Systèmes d'Information;

AvoHILMO = Register of Primary Health Care Visits;

Finnish EMR;

Prescription Registers Finland.

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

[Drug prescriptions](#)

[Electronic healthcare records \(EHR\)](#)

[Pharmacy dispensing records](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown